drugset / Trial / NCT06995573
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of NSC001 on in patients with mild to moderate Alzheimer's disease and to evaluate the influence of the compound on cognitive function.
Timeline
- Start
- 2025-08-25
- Primary completion
- 2026-07-30
- Completion
- 2026-09-30
Publications
- Background Fisher A. Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer's disease. J Neurochem. 2012 Jan;120 Suppl 1:22-33. doi: 10.1111/j.1471-4159.2011.07507.x. Epub 2011 Nov 28.
- Background Fisher A. Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease. Neurotherapeutics. 2008 Jul;5(3):433-42. doi: 10.1016/j.nurt.2008.05.002.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NSC001 | Small molecule | 40 mg | Oral |